Ypsomed Sells Pen Needle and BGM Business to Focus on Insulin Pump Solutions

Ypsomed will transfer its pen needle and blood glucose monitoring (BGMs) businesses to Medical Technology and Devices S.p.A. (MTD), a leading medical technology group focused on diabetes care devices.

With the sale of the pen needles and BGMs business, which generated sales of CHF 52 million in FY 2022/23, Ypsomed will focus on its diabetes care business and invest over CHF 100 million in the expansion of autoinjector capacity at the Solothurn site over the next four years.

During a transition period, Ypsomed will produce pen needles as a contract manufacturer and provide certain services to ensure a seamless transfer. The production facilities will be gradually transferred to the MTD sites by mid-2025.

I am convinced that MTD will successfully integrate our pen needle and BGM products into their existing portfolio. At Ypsomed Diabetes Care, we are now fully focusing on our insulin pump solutions,” said Simon Michel, CEO of Ypsomed.

To view the source version, please click HERE.

en_GBEnglish (UK)